Aurinia Pharmaceuticals AUPH Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $298.21M+648% | $287.2M+4,893% | $77.84M+445% | $60.64M+220% | $39.85M+164% | ||
| $19.41M-0.2% | $19.45M0.0% | $19.45M-0.4% | $19.48M-2.1% | $19.45M+23.3% | ||
| $17.22M-23.3% | $14.68M-53.5% | $16.9M-50.9% | $19.3M-49.1% | $22.45M-46.0% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$2.14M-281% | ||
| $1.94M— | $200K— | -$5.42M— | —— | —— | ||
| —— | —— | —— | $11.58M+836% | $10.13M+259% | ||
| —— | —— | —— | —— | —— | ||
| -$821K-7.5% | -$802K-6.9% | -$800K-10.5% | -$780K-8.5% | -$764K-9.5% | ||
| $9.08M— | $5.17M— | -$5.5M— | $14.83M— | —— | ||
| $166.92M+160% | $135.66M+206% | $120.1M— | $92.68M— | $64.29M— | ||
| —— | —— | —— | —— | —— | ||
| $87.4M+16.8% | $98.16M+144% | $119.96M+551% | $111.29M+504% | $74.86M+509% | ||
| —— | —— | —— | —— | —— | ||
| $16.79M+13.7% | $15.91M+7.7% | $15.45M-15.5% | $14.96M-20.4% | $14.76M+15.3% | ||
| $15.41M+61.0% | $9.76M+59.2% | $9.64M+49.2% | $9.45M+37.6% | $9.57M+32.8% | ||
| -$110.46M-32.5% | -$106.11M-116% | -$127.27M-302% | -$119.5M-283% | -$83.38M-282% | ||
| —— | —— | —— | $19.6M+139% | $1.97M+107% | ||
| $4.17M+71.7% | $3.09M+41.6% | $3.82M+136% | $1.79M+6.7% | $2.43M+391% | ||
| $9.84M-19.2% | $10.18M-20.0% | $10.82M-17.1% | $11.62M-9.7% | $12.18M-4.4% | ||
| -$7.46M— | -$9.69M— | -$4.13M— | —— | —— | ||
| —— | —— | —— | —— | -$2.14M-281% | ||
| -$821K-7.5% | -$802K-6.9% | -$800K-10.5% | -$780K-8.5% | -$764K-9.5% | ||
| —— | —— | —— | —— | —— | ||
| $1.94M— | $200K— | -$5.42M— | —— | —— | ||
| $274K-4.2% | $252K-10.3% | $236K-55.0% | $256K— | $286K— | ||
| $16.79M+13.7% | $15.91M+7.7% | $15.45M-15.5% | $14.96M-20.4% | $14.76M+15.3% | ||
| —— | —— | —— | $11.58M+836% | $10.13M+259% | ||
| -$821K-7.5% | -$802K-6.9% | -$800K-10.5% | -$780K-8.5% | -$764K-9.5% | ||
| —— | $3.77M— | $2.83M— | $1.89M— | $943.25K— | ||
| $4.17M+71.7% | $3.09M+41.6% | $3.82M+136% | $1.79M+6.7% | $2.43M+391% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Aurinia Pharmaceuticals generate?
- Aurinia Pharmaceuticals (AUPH) generated $166.9M in operating cash flow over the trailing twelve months.
- Where does Aurinia Pharmaceuticals's cash flow data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
